Ten years of sirolimus therapy in orthotopic liver transplant recipients

G. W. Neff, M. Montalbano, A. G. Tzakis

Research output: Contribution to journalArticlepeer-review


Background. Sirolimus therapy has been used in orthotopic liver transplant (OLT) recipients diagnosed with a variety of diseases; chronic graft rejection (CR), calcineurin associated renal toxicity, preemptive immune suppression, calcineurin related neurotoxicity, preemptive therapy in transplant recipients with history of hepatocellular carcinoma, and steroid resistant allograft rejection. Methods. A search for the medical literature and experiences involving sirolimus was done. Results. Several animal and human reports evaluating the use sirolimus in liver transplant recipients are found and discussed. Conclusion Sirolimus has been used for multitude of indications, primarily based on anecdotal experiences. However, reports of sirolimus related side effects have decreased the transplant communities' enthusiasm towards promoting this agent as a safe immune suppression agent.

Original languageEnglish
JournalTransplantation Proceedings
Issue number3 SUPPL.
Publication statusPublished - May 2003

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Ten years of sirolimus therapy in orthotopic liver transplant recipients'. Together they form a unique fingerprint.

Cite this